KOFCLEAN COMBINATION PRODUCT SYRUP

Dosage

Children: Refer to a qualified healthcare professional for appropriate dosing information.

Adults: Refer to a qualified healthcare professional for appropriate dosing information.

Pregnancy

Safety during pregnancy has not been established; use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is unknown whether this drug is excreted in human milk; caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Gastrointestinal disorders (e.g., peptic ulcers, dyspepsia)
• Respiratory conditions (e.g., cough, bronchitis)
• Inflammatory conditions (e.g., arthritis, dermatitis)
• Viral infections (e.g., hepatitis, herpes simplex)

Dosage

Children: Refer to established clinical guidelines for appropriate dosing, as no specific dose is provided.

Adults: Refer to established clinical guidelines for appropriate dosing, as no specific dose is provided.

Mechanism of action

Glycyrrhizin, the active compound in glabra, inhibits the enzyme 11β-hydroxysteroid dehydrogenase type 2, leading to increased cortisol levels in tissues. This mechanism helps to reduce inflammation and modulate immune responses. Additionally, glabra exhibits antiviral activity by inhibiting the replication of certain viruses, possibly through interference with viral proteins and host cell interactions.

Pharmacodynamics

The pharmacodynamic effects of glabra are primarily attributed to glycyrrhizin and flavonoids present in the plant. Its anti-inflammatory effects are mediated through the inhibition of pro-inflammatory cytokines and pathways such as NF-κB. The compound also has expectorant properties, aiding in the relief of cough and respiratory distress by promoting mucus secretion and reducing irritation in the airways.

Pharmacokinetics

Glycyrrhizin is absorbed in the gastrointestinal tract, and its bioavailability can be influenced by the presence of other food components. Once absorbed, it undergoes hepatic metabolism, with its metabolites excreted primarily through urine. The half-life of glycyrrhizin can vary but is generally several hours, necessitating multiple doses for sustained therapeutic effects. Chronic use may lead to accumulation and potential side effects such as hypertension and hypokalemia due to its mineralocorticoid-like effects.

Pregnancy

The safety of glabra during pregnancy has not been established. It is advisable to avoid its use unless clearly needed.

Breast-feeding

There is limited information on the excretion of glabra in human milk. Caution is advised when administering to breastfeeding mothers.

Storage

Store at room temperature, away from moisture and direct light. Keep out of reach of children.

Indications

• Adrenal insufficiency
• Chronic inflammatory conditions

Mechanism of action

Glycyrrhizin, the primary active component of Glycyrrhiza, exerts its effects primarily through inhibition of the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). This inhibition prevents the conversion of active cortisol to inactive cortisone, leading to increased cortisol levels. Elevated cortisol mimics the effects of aldosterone, resulting in sodium retention, potassium excretion, and increased blood pressure. Additionally, licorice has anti-inflammatory and antiviral properties attributed to its ability to modulate various immune pathways and inhibit viral replication.

Pharmacodynamics

The pharmacodynamic effects of Glycyrrhiza include anti-inflammatory, antiviral, and immunomodulatory activities. Glycyrrhizin has been shown to reduce inflammation by inhibiting the production of pro-inflammatory cytokines and mediators. Its potential antiviral properties are particularly noted in viral infections such as hepatitis C and COVID-19, where it may inhibit viral replication. Furthermore, its ability to enhance the effects of corticosteroids can be beneficial in treating conditions associated with adrenal insufficiency or chronic inflammation.

Pharmacokinetics

Glycyrrhizin is absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1-2 hours after oral administration. It undergoes extensive metabolism in the liver, primarily through conjugation processes, leading to the formation of glycyrrhetic acid as a major metabolite. The elimination half-life of glycyrrhizin is approximately 6-8 hours. Glycyrrhiza components are excreted in urine predominantly as conjugated forms. Long-term use can lead to accumulation and potential side effects due to its mineralocorticoid-like effects.

Contra-indications

• Hypertension
• Hypokalemia
• Severe kidney disease
• Pregnancy (due to hormonal effects)

Adverse effects

• Hypertension
• Hypokalemia
• Edema
• Headaches
• Fatigue
• Muscle weakness
• Cardiac arrhythmias (with excessive use)

Interactions

• May enhance the effects of corticosteroids
• May increase the risk of hypokalemia with diuretics
• May interact with anticoagulants, increasing the risk of bleeding
• May affect the metabolism of drugs metabolized by CYP3A4

Precautions

• Use with caution in patients with cardiovascular disease
• Monitor blood pressure and potassium levels during prolonged use
• Not recommended for long-term use without medical supervision

Pregnancy

Glycyrrhiza should be avoided during pregnancy as it may cause hormonal effects that could affect fetal development.

Breast-feeding

Consult a healthcare provider before use while breastfeeding, as safety is not well established.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Formulations

• Dried root
• Extracts (liquid and powdered)
• Teas
• Capsules

Indications

• Irritable bowel syndrome (IBS)
• Diarrhea
• Constipation
• Gut dysbiosis
• Support for immune function
• Enhancement of gut health

Dosage

Adults: Refer to specific product guidelines and consult a healthcare professional for dosing recommendations, as doses can vary based on formulation and intended

Mechanism of action

Bifidobacterium longum exerts its beneficial effects primarily through the modulation of the gut microbiota. It helps in the fermentation of dietary fibers, producing short-chain fatty acids (SCFAs) that nourish colon cells and maintain gut barrier integrity. Moreover, it competes for adhesion sites and nutrients against pathogenic bacteria, thereby inhibiting their growth. This strain also has immunomodulatory effects, enhancing the host's immune response by promoting the production of anti-inflammatory cytokines and increasing the activity of immune cells.

Pharmacodynamics

The pharmacodynamics of Bifidobacterium longum involve its ability to balance the gut microbiome, enhance mucosal immunity, and improve intestinal permeability. It has been shown to lower the pH of the gut, creating an unfavorable environment for pathogenic organisms. Additionally, it can alleviate symptoms associated with gastrointestinal disorders such as irritable bowel syndrome (IBS), diarrhea, and constipation by promoting regular bowel movements and reducing inflammation in the gut.

Pharmacokinetics

Bifidobacterium longum is not absorbed into the systemic circulation but acts locally within the gastrointestinal tract. Its effects are primarily exerted in the intestines, where it colonizes and interacts with the gut environment. The survival and efficacy of this probiotic can be influenced by factors such as the formulation, dosage, and the individual's existing gut microbiota. Generally, ingestion of probiotics leads to transient colonization, with the bacteria being excreted in feces within a few days after discontinuation of use.

Pregnancy

Safety during pregnancy has not been established. Consult healthcare professionals before use.

Breast-feeding

Safety during breastfeeding has not been established. Consult healthcare professionals before use.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Indications

• Digestive disorders
• Respiratory conditions
• Antimicrobial therapy
• Anti-inflammatory support
• Stress relief

Dosage

Children: Refer to specific herbal preparation guidelines; there is no standard paediatric dose for Ocimum.

Adults: Refer to specific herbal preparation guidelines; there is no standard adult dose for Ocimum.

Mechanism of action

The pharmacological effects of Ocimum are primarily attributed to its essential oil constituents, such as eugenol, linalool, and other phenolic compounds. These compounds exert their effects through the modulation of various signaling pathways, including the inhibition of pro-inflammatory cytokines and the promotion of antioxidant defense mechanisms. The antimicrobial properties are believed to arise from the disruption of microbial cell membranes and interference with metabolic processes.

Pharmacodynamics

Ocimum exhibits a range of pharmacodynamic properties, including anti-inflammatory, antioxidant, and antimicrobial effects. The essential oils have been shown to reduce oxidative stress and inflammation, which can be beneficial in managing conditions related to chronic inflammation. Additionally, the herb may promote digestive health by enhancing gastrointestinal motility and reducing symptoms of dyspepsia.

Pharmacokinetics

The pharmacokinetics of Ocimum's active constituents vary, but generally, essential oils are readily absorbed through the gastrointestinal tract and metabolized in the liver. The bioavailability of these compounds can be influenced by the method of preparation (e.g., fresh, dried, or extract form) and the presence of other food components. The elimination half-life is also variable and dependent on the specific compounds involved.

Pregnancy

Limited data is available on the safety of Ocimum during pregnancy. It is advisable to use with caution and consult a healthcare provider.

Breast-feeding

Due to lack of sufficient evidence, it is recommended to consult a healthcare provider before use during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Essential oil
• Dried leaves
• Tincture
• Powder

Indications

• Uncomplicated malaria caused by Plasmodium falciparum

Dosage

Children: Refer to the BNF for Children for appropriate dosing in paediatric patients.

Adults: Refer to the BNF for specific dosing recommendations.

Mechanism of action

Piperaquine acts by interfering with the heme detoxification process in the malaria parasite. It accumulates within the food vacuole of the parasite and inhibits the conversion of toxic heme into non-toxic hemozoin. This accumulation of free heme leads to oxidative stress and cellular damage, ultimately resulting in the death of the parasite.

Pharmacodynamics

Piperaquine demonstrates a dose-dependent response in its antimalarial activity. It is effective against the asexual blood stages of Plasmodium species, with a prolonged half-life that allows for once-weekly dosing in some regimens. The drug's efficacy is influenced by the rate of parasite clearance and the patient's immune response.

Pharmacokinetics

Piperaquine is well-absorbed following oral administration, with peak plasma concentrations typically occurring within 4 to 6 hours. It has a long elimination half-life, which can range from 10 to 30 days, allowing for sustained plasma levels. The drug is metabolized in the liver and excreted primarily in the feces, with a smaller fraction eliminated in the urine. Its pharmacokinetics can be significantly affected by drug interactions, particularly those that alter hepatic metabolism.

Interactions

• grapefruit juice: Severe (increases concentration)
• mitotane: Severe (decreases concentration)
• St. John's wort: Severe (decreases concentration)
• rifampicin: Severe (decreases concentration)
• dronedarone: Unknown (increases concentration)
• cobicistat: Unknown (increases concentration)
• crizotinib: Unknown (increases concentration)
• idelalisib: Unknown (increases concentration)
• imatinib: Unknown (increases concentration)
• letermovir: Unknown (increases concentration)

Pregnancy

Consult with a healthcare professional regarding the use of piper during pregnancy.

Breast-feeding

Consult with a healthcare professional regarding the use of piper during breastfeeding.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• {'name': 'Piperaquine', 'class': 'Penicillins', 'molecular_formula': 'C38H36N4O4'}

Dosage

Children: Specific dosing information for paediatric patients is not available. It is advisable to consult paediatric dosing guidelines or healthcare professionals for appropriate dosing recommendations.

Adults: Specific dosing information for adults is not available. It is recommended to refer to clinical guidelines or consult a healthcare professional for appropriate dosing recommendations.

Mechanism of action

The exact mechanism of action of Sanctum is currently unclear. However, it may involve modulation of specific biochemical pathways or receptors that influence physiological processes related to its therapeutic effects. Further studies are needed to elucidate its pharmacological properties.

Pharmacodynamics

Pharmacodynamics of Sanctum may involve interactions with cellular receptors or enzymes that lead to altered cellular functions. These interactions could affect various biological systems, potentially resulting in therapeutic outcomes. The specific pharmacodynamic profile remains to be characterized.

Pharmacokinetics

The pharmacokinetic properties of Sanctum, including absorption, distribution, metabolism, and excretion, have not been well-defined in the literature. It is essential to conduct comprehensive studies to determine how the drug behaves in the body and its potential impact on therapeutic effectiveness.

Indications

• Antioxidant support
• Cardiovascular health
• Anti-inflammatory effects
• Improvement of blood circulation
• Support for skin health

Dosage

Children: Specific pediatric dosing information is not available. It is recommended to consult healthcare professionals for guidance on use in children.

Adults: Dosage can vary widely based on the formulation (e.g., whole grape, extract, supplement) and intended use. It is advisable to refer to specific product guidelines or consult a healthcare provider for appropriate dosing recommendations.

Mechanism of action

The active compounds in Vitis vinifera, particularly flavonoids and polyphenols, exert their effects primarily through their antioxidant properties. They scavenge free radicals, reducing oxidative stress and inflammation in the body. Additionally, these compounds may enhance endothelial function, improve blood flow, and reduce the risk of cardiovascular diseases by modulating nitric oxide synthesis and inhibiting platelet aggregation.

Pharmacodynamics

Vinifera exhibits a range of pharmacological effects, primarily due to its high content of polyphenolic compounds. These compounds have been shown to exhibit anti-inflammatory, antioxidant, and anticancer properties. The antioxidant capacity of grape extracts can help neutralize reactive oxygen species, thereby protecting cells from oxidative damage. Moreover, studies have indicated potential benefits in cardiovascular health, including improved circulation and lower blood pressure.

Pharmacokinetics

The bioavailability of polyphenols from Vitis vinifera can vary significantly depending on the form of consumption and individual metabolism. After ingestion, these compounds are absorbed in the gastrointestinal tract, but their absorption is often limited. They undergo extensive metabolism in the liver and can be converted into various metabolites. The elimination half-life of these compounds is variable and can depend on factors such as dosage, formulation, and individual differences in metabolism.

Pregnancy

Limited data are available on the use of vinifera during pregnancy. It is advisable to consult a healthcare professional before use.

Breast-feeding

There is insufficient data on the excretion of vinifera in human milk. Caution is recommended when using this substance during breastfeeding.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Overactive bladder syndrome
• Urinary incontinence
• Urgency
• Frequent urination

Dosage

Children: Refer to the BNF for Children for pediatric dosing information.

Adults: Refer to the BNF for specific dosing recommendations.

Mechanism of action

Solifenacin selectively blocks the muscarinic M3 receptors in the bladder detrusor muscle. By inhibiting these receptors, solifenacin reduces involuntary bladder contractions, thereby increasing bladder storage capacity and decreasing the urgency and frequency of urination.

Pharmacodynamics

The pharmacodynamics of visica involve its role as a competitive antagonist of muscarinic receptors. Its selectivity for M3 receptors contributes to its therapeutic effects in managing overactive bladder without significant effects on heart rate or salivation, which are mediated by M2 receptors. The onset of action is typically observed within a few hours, with maximum effects seen after several days of consistent use.

Pharmacokinetics

Visica is well absorbed following oral administration, with peak plasma concentrations occurring approximately 3 to 8 hours post-dose. It has a large volume of distribution, indicating extensive tissue binding. The drug is metabolized predominantly by the liver, primarily through cytochrome P450 enzymes, and has an elimination half-life of about 45 to 68 hours. Renal excretion accounts for a small percentage of the drug's elimination, with most metabolites being excreted in the feces.

Contra-indications

• Hypersensitivity to the active substance or any of the excipients
• Severe urinary retention
• Myasthenia gravis
• Pyloric stenosis

Adverse effects

• Dry mouth
• Constipation
• Dizziness
• Blurred vision
• Nausea
• Headache
• Fatigue

Interactions

• Anticholinergic drugs may increase the risk of adverse effects
• CYP3A4 inhibitors may increase plasma concentrations of the drug
• CYP3A4 inducers may decrease plasma concentrations of the drug

Precautions

• Use with caution in patients with a history of urinary retention
• Caution in patients with gastrointestinal disorders
• Monitor for signs of anticholinergic effects
• Use cautiously in elderly patients due to increased sensitivity

Pregnancy

Not recommended during pregnancy unless clearly necessary. Potential risks should be weighed against benefits.

Breast-feeding

Use with caution. Limited data available; monitor infant for adverse reactions.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Tablets
• Extended-release capsules

Indications

• Antioxidant support
• Cardiovascular health
• Anti-inflammatory effects
• Potential anti-cancer properties

Dosage

Children: There is insufficient data on the safety and efficacy of Vitis or its extracts in the pediatric population. Consult a healthcare professional for guidance.

Adults: Dosing for Vitis products varies widely based on the formulation and intended use. Standard doses of resveratrol supplements often range from 100 mg to 500 mg per day. Users should refer to specific product guidelines.

Mechanism of action

The polyphenolic compounds in Vitis exhibit antioxidant properties, which help to neutralize free radicals in the body. Resveratrol, in particular, has been shown to activate sirtuins, a group of proteins that regulate cellular processes including aging and inflammation. These compounds may also influence nitric oxide pathways, leading to improved vascular function and reduced platelet aggregation.

Pharmacodynamics

The pharmacodynamic effects of Vitis are largely attributed to its antioxidant and anti-inflammatory properties. It may protect against oxidative stress, support cardiovascular health by improving endothelial function, and exhibit potential anti-cancer effects. Additionally, the anti-inflammatory properties may help in conditions associated with chronic inflammation.

Pharmacokinetics

The bioavailability of resveratrol is relatively low due to extensive first-pass metabolism. After oral administration, it is rapidly absorbed and metabolized in the gastrointestinal tract and liver. The primary metabolites are glucuronides and sulfates, which are excreted in urine. The half-life can vary significantly based on dosing and individual metabolism.

Pregnancy

There is insufficient reliable information regarding the safety of vitis during pregnancy. It is advisable to consult a healthcare professional before use.

Breast-feeding

Limited information is available on the excretion of vitis components in breast milk. Caution is advised when using during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Ensure the product is kept out of reach of children.